Source comparison
Wolverine Stack for ACL Recovery: Comparison
BPC-157 VEGF upregulation → angiogenesis, NF-κB modulation → inflammation control 250–500 mcg per dose Twice daily (acute phase), once daily (remodeling phase) Increases blood vessel density at injury site, accelerates tendon-to-bone healing Limited human clin
This comparison does not assign a generated winner or score.
- BPC-157
- VEGF upregulation → angiogenesis, NF-κB modulation → inflammation control
- 250–500 mcg per dose
- Twice daily (acute phase), once daily (remodeling phase)
- Increases blood vessel density at injury site, accelerates tendon-to-bone healing
- Limited human clinical trials. Most data from animal models
- TB-500
- Actin polymerization → cell migration, collagen I gene expression
- 2.5–5 mg (loading), 2.5 mg (maintenance)
- Twice weekly (weeks 1–3), once weekly (weeks 4–8)
- Enhances fibroblast migration and organized collagen deposition
- Requires consistent dosing. Missed injections reduce cumulative effect
- Wolverine Stack (Both)
- Dual-pathway: vascular + cellular scaffolding
- BPC-157 + TB-500 as above
- Per individual peptide schedule
- Addresses two rate-limiting steps in soft tissue repair simultaneously
- Higher cost, more complex administration than single-peptide protocols